Latest News

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.

Catch up on this week's highlights in retina.

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc, aiming to revolutionize eye care with advanced predictive health insights.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Catch up on this week's highlights in retina.

A recent study reveals that systemic chemotherapy significantly reduces mortality and enucleation rates in retinoblastoma, enhancing patient outcomes.

While the STAR trial showed significant reductions in myopia progression, including over 50% in fast-progressing children, the FDA requires additional evidence to support US approval.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

During the American Academy of Ophthalmology annual scientific meeting, the organization shared breaking news and updates from ongoing projects.

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.

The topical therapy offers a less invasive approach to corneal cross-linking, with commercial availability anticipated in early 2026.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration.

DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases.

Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.

Catch up on this week's highlights in retina.

AAO attendees can preview the new technician training platform on Sunday, October 19.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

The FDA describes the RDEA pilot program as a program to support novel endpoint efficacy development for drugs that treat rare diseases.

This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

The video-driven platform will improve workflow, education and engagement, said Inder Paul Singh, MD.